Bristol-Myers Squibb Co. has agreed to pay $450 million to settle class action suits from shareholders and separate civil claims by the Securities and Exchange Commission. The settlements stem from Bristol’s practice of building up wholesalers’ inventories and diverting operating income to enhance dividends.
Trending Stories
- As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded - Proposed OMB rule aims at the heart of the U.S. research enterprise—and scientists are fighting back
“The question isn’t whether politics will influence research. Under this proposal, that’s the point. That’s their goal.” - Pancreatic cancer breakthrough came from smart scientists making smart bets—not from politicization of science
- House bill gives NCI $7.4 billion in FY 2027—$110 million above current budget
- NIH calls for comment on proposal to limit the number of RPGs per PI
- The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe









